沙美特罗/丙酸氟替卡松治疗稳定期COPD患者的临床观察

Clinical Observation of Inhalation Therapy of Salmeterol/fluticasone(50/500) for Non-smoking Stable stage of Chronic Obstructive Pulmonary Disease

目的探讨吸入型沙美特罗/丙酸氟替卡松(50/500)对非吸烟、稳定期COPD的治疗效果。方法因AECOPD住院后经治疗缓解的出院患者133例,随机分成3组,吸烟组52例,非吸烟组36例,吸入沙美特罗/丙酸氟替卡松(50/500)治疗,对照组45例,不吸入上述药物;3组患者随访12月,记录治疗前后SGRQ、肺功能、急性加重次数等。结果吸烟组治疗前后比较,肺功能、SGRQ明显改善,急性加重次数明显减少(P<0.05);而在非吸烟组和对照组上述指标治疗前后无显著差别(P>0.05)。结论沙美特罗/丙酸氟替卡松(50/500)可以改善吸烟组COPD患者生存状态、改善肺功能和减少急性加重,而非吸烟、稳定期COPD患者并没有从沙美特罗/丙酸氟替卡松(50/500)治疗中获益。

Objective To discuss the treatment effects of inhaled salmeterol/fluticasone（50/500） for non-smoking stable stage chronic obstructive pulmonary disease（COPD）.Methods 133 patients with COPD were randomly divided into 3 groups.They had been hospitalized for acute-exacerbation COPD.Smoking group was 52 cases,non-smoking group was 36 cases,both were given inhaled salmeterol/fluticasone propionate（50/500） treatment,and the control group was 45 cases without the drug.All patients were followed up for 12 months,record SGRQ scores,pulmonary function and times of acute exacerbations at the treatment.Results Compared with before treatment in Smoking group,pulmonary function improved notabily,SGRQ total scores improved significantly,acute exacerbation has diminished significantly（P0.05）.These indexes were no significant difference between non-smoking group and the control group（P0.05）.Conclusion Inhalation therapy of Salmeterol/fluticasone propionate（50/500） can improve the quality of life and lung function,reduce acute exacerbations in smoking patients with stable stage COPD,but non-smoking patients can not benefit from it.